MarketCapExport financials
Collegium Pharmaceutical (COLL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Collegium Pharmaceutical Balance Sheet 2025-2011 | COLL
Brief overview of Collegium Pharmaceutical's balance sheet structure
This overview follows the five latest available annual observations between 2021 and 2025.
Assets advanced +139.4% to $1.7 billion from $692.1 million; annual growth near 24.4% reflects a fast increase in scale.
Liability growth of +177% exceeded asset growth of +139.4%, increasing reliance on outside funding.
The equity ratio is 18.2%, compared with 29.3% before. Low autonomy increases reliance on liabilities.
Negative net debt of -$225.7 million means cash holdings are larger than debt obligations.
Cash accounts for 14% of assets versus 26.9% initially. The change indicates the degree of financial flexibility.
The balance sheet includes a negative accumulated result of -$101.1 million. It should be assessed alongside historical profits and capital distributions.
Conclusion
Collegium Pharmaceutical's balance sheet presents a mixed picture: strengths coexist with a limited cushion. Future capital and debt trends are particularly important.
Annual Balance Sheet Collegium Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-226 M | -63.8 M | -232 M | -165 M | -178 M | -165 M | -159 M | -135 M | -117 M | -149 M | -88.9 M | 11.4 M | -6.58 M | - | - |
Long Term Debt |
4.13 M | 5.54 M | 6.12 M | 7.11 M | 7.95 M | 8.76 M | 7.67 M | 9.86 M | - | 1.48 M | 4.15 M | 6.81 M | 640 K | - | - |
Long Term Debt Current |
1.41 M | 1.27 M | 988 K | 1.11 M | 814 K | 730 K | 656 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
915 M | 925 M | 490 M | 546 M | 210 M | 218 M | 17.1 M | 10.5 M | - | 1.51 M | 4.21 M | 6.91 M | 834 K | - | - |
Total Current Liabilities |
440 M | 510 M | 458 M | 434 M | 280 M | 239 M | 202 M | 189 M | 31.5 M | 25.6 M | 8.43 M | - | - | - | - |
Total Liabilities |
1.36 B | 1.43 B | 948 M | 979 M | 489 M | 458 M | 219 M | 200 M | 31.5 M | 27.1 M | 12.6 M | 17.3 M | 3.45 M | - | - |
Deferred Revenue |
667 K | - | - | - | - | - | - | - | - | 4.94 M | - | - | - | - | - |
Retained Earnings |
-101 M | -164 M | -233 M | -281 M | -256 M | -333 M | -360 M | -337 M | -298 M | -223 M | -129 M | -102 M | -80.5 M | - | - |
Total Assets |
1.66 B | 1.66 B | 1.14 B | 1.17 B | 692 M | 644 M | 306 M | 291 M | 136 M | 162 M | 97.7 M | 5.09 M | 9.03 M | - | - |
Cash and Cash Equivalents |
231 M | 70.6 M | 239 M | 174 M | 186 M | 174 M | 170 M | 147 M | 119 M | 153 M | 95.7 M | 1.63 M | 7.55 M | - | - |
Book Value |
302 M | 229 M | 195 M | 195 M | 203 M | 186 M | 87.4 M | 91.6 M | 104 M | 135 M | 85.1 M | -12.2 M | 5.58 M | - | - |
Total Shareholders Equity |
302 M | 229 M | 195 M | 195 M | 203 M | 186 M | 87.4 M | 91.6 M | 104 M | 135 M | 85.1 M | -89.3 M | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Collegium Pharmaceutical
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.9 M | 3.41 M | 3.79 M | 4.13 M | 4.5 M | 4.85 M | 5.2 M | 5.54 M | 5.91 M | 5.59 M | 5.86 M | 6.12 M | 6.38 M | 6.63 M | 6.87 M | 7.11 M | 7.35 M | 7.6 M | 7.91 M | 7.95 M | 8.17 M | 8.37 M | 8.57 M | 8.76 M | 8.96 M | 9.08 M | 9.26 M | 9.44 M | 9.61 M | 9.9 M | 10.1 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | - | - | - | - | 4.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
1.2 B | 1.23 B | 905 M | 915 M | 880 M | 896 M | 910 M | 925 M | 941 M | 375 M | 446 M | 490 M | 534 M | 578 M | 622 M | 546 M | 589 M | 633 M | 676 M | 210 M | 222 M | 234 M | 246 M | 218 M | 229 M | 239 M | 249 M | 17.1 M | 18.2 M | 19.5 M | 19.1 M | 10.5 M | 296 M | 326 M | 355 M | - | 8 K | 441 K | 949 K | 1.51 M | 2.19 M | 2.86 M | 3.54 M | 4.21 M | 4.89 M | 5.56 M | 6.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.8 B | 1.82 B | 1.34 B | 1.36 B | 1.33 B | 1.36 B | 1.4 B | 1.43 B | 1.4 B | 837 M | 892 M | 948 M | 999 M | 1.01 B | 1.03 B | 979 M | 1 B | 1.05 B | 1.05 B | 489 M | 491 M | 461 M | 476 M | 458 M | 471 M | 491 M | 494 M | 219 M | 220 M | 216 M | 208 M | 200 M | 576 M | 591 M | 605 M | 31.5 M | 26.4 M | 29 M | 25.5 M | 27.1 M | 24.4 M | 21.1 M | 14.6 M | 12.6 M | 13.5 M | 11.8 M | 12.9 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.78 M | 667 K | 667 K | 667 K | 667 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-79.9 M | -102 M | -86.6 M | -101 M | -118 M | -150 M | -162 M | -164 M | -177 M | -186 M | -205 M | -233 M | -265 M | -286 M | -299 M | -281 M | -274 M | -275 M | -269 M | -256 M | -231 M | -239 M | -312 M | -333 M | -340 M | -351 M | -359 M | -360 M | -358 M | -352 M | -347 M | -337 M | -346 M | -330 M | -317 M | -298 M | -281 M | -267 M | -246 M | -223 M | -196 M | -169 M | -145 M | -129 M | -119 M | -110 M | -105 M | -102 M | -102 M | -102 M | -102 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.1 B | 2.14 B | 1.65 B | 1.66 B | 1.61 B | 1.59 B | 1.63 B | 1.66 B | 1.64 B | 1.05 B | 1.11 B | 1.14 B | 1.18 B | 1.21 B | 1.21 B | 1.17 B | 1.2 B | 1.25 B | 1.25 B | 692 M | 742 M | 714 M | 646 M | 644 M | 644 M | 647 M | 635 M | 306 M | 304 M | 302 M | 294 M | 291 M | 647 M | 673 M | 696 M | 136 M | 123 M | 125 M | 140 M | 162 M | 98.7 M | 120 M | 136 M | 97.7 M | 107 M | 114 M | 47.4 M | 5.09 M | 5.09 M | 5.09 M | 5.09 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
166 M | 150 M | 290 M | 252 M | 171 M | 138 M | 117 M | 96.6 M | 65 M | 174 M | 230 M | 240 M | 260 M | 285 M | 272 M | 176 M | 137 M | 125 M | 109 M | 189 M | 196 M | 205 M | 185 M | 177 M | 168 M | 148 M | 119 M | 170 M | 154 M | 149 M | 135 M | 147 M | 140 M | 134 M | 129 M | 119 M | 108 M | 111 M | 130 M | 153 M | 91 M | 111 M | 135 M | 95.8 M | 105 M | 112 M | 45 M | 1.63 M | 1.63 M | 1.63 M | 1.63 M | 7.55 M | - | - | - | 11.9 M | - | - | - | - | - | - | - |
Book Value |
296 M | 312 M | 312 M | 302 M | 275 M | 232 M | 234 M | 229 M | 234 M | 217 M | 222 M | 195 M | 179 M | 201 M | 180 M | 195 M | 197 M | 198 M | 196 M | 203 M | 251 M | 253 M | 170 M | 186 M | 173 M | 156 M | 141 M | 87.4 M | 84.3 M | 85.8 M | 86.4 M | 91.6 M | 70.8 M | 82.7 M | 90.8 M | 104 M | 96.3 M | 95.5 M | 114 M | 135 M | 74.3 M | 98.7 M | 122 M | 85.1 M | 93.6 M | 102 M | 34.4 M | -12.2 M | -12.2 M | -12.2 M | -12.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
296 M | 312 M | 312 M | 302 M | 275 M | 232 M | 234 M | 229 M | 234 M | 217 M | 222 M | 195 M | 179 M | 201 M | 180 M | 195 M | 197 M | 198 M | 196 M | 203 M | 251 M | 253 M | 170 M | 186 M | 173 M | 156 M | 141 M | 87.4 M | 84.3 M | 85.8 M | 86.4 M | 91.6 M | 70.8 M | 82.7 M | 90.8 M | 104 M | 96.3 M | 95.5 M | 114 M | 135 M | 74.3 M | 98.7 M | 122 M | 85.1 M | 93.6 M | 102 M | -85.2 M | -89.3 M | -89.3 M | -89.3 M | -89.3 M | -68.2 M | - | - | - | -61.4 M | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Collegium Pharmaceutical, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Irlanda
Israel
Britain
Schweiz
Canada
